156 related articles for article (PubMed ID: 38551394)
1. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Yarchoan M; Powderly JD; Bastos BR; Karasic TB; Crysler OV; Munster PN; McKean MA; Emens LA; Saenger YM; Ged Y; Stagg R; Smith S; Whiting CC; Moon A; Prasit P; Jenkins Y; Standifer N; Dubensky TW; Whiting SH; Ulahannan SV
Cancer Res Commun; 2024 Apr; 4(4):1100-1110. PubMed ID: 38551394
[TBL] [Abstract][Full Text] [Related]
2. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
Silk AW; Saraiya B; Groisberg R; Chan N; Spencer K; Girda E; Shih W; Palmeri M; Saunders T; Berman RM; Coric V; Chen S; Zloza A; Vieth J; Mehnert JM; Malhotra J
Eur J Med Res; 2022 Jul; 27(1):107. PubMed ID: 35780243
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
[TBL] [Abstract][Full Text] [Related]
4. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Choueiri TK; Atkins MB; Rose TL; Alter RS; Ju Y; Niland K; Wang Y; Arbeit R; Parasuraman S; Gan L; McDermott DF
Invest New Drugs; 2021 Aug; 39(4):1019-1027. PubMed ID: 33507454
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Markham A
Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
[TBL] [Abstract][Full Text] [Related]
7. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
[TBL] [Abstract][Full Text] [Related]
8. First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Do KT; Chow LQM; Reckamp K; Sanborn RE; Burris H; Robert F; Camidge DR; Steuer CE; Strickler JH; Weise A; Specht JM; Gutierrez M; Haughney P; Hengel S; Derleth CL; Yap TA
Oncologist; 2021 Nov; 26(11):925-e1918. PubMed ID: 34288257
[TBL] [Abstract][Full Text] [Related]
9. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
11. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.
Abu Aboud O; Donohoe D; Bultman S; Fitch M; Riiff T; Hellerstein M; Weiss RH
Am J Physiol Cell Physiol; 2015 Jun; 308(11):C890-8. PubMed ID: 25810260
[TBL] [Abstract][Full Text] [Related]
12. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
[TBL] [Abstract][Full Text] [Related]
13. OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Gutierrez M; Moreno V; Heinhuis KM; Olszanski AJ; Spreafico A; Ong M; Chu Q; Carvajal RD; Trigo J; Ochoa de Olza M; Provencio M; De Vos FY; De Braud F; Leong S; Lathers D; Wang R; Ravindran P; Feng Y; Aanur P; Melero I
Clin Cancer Res; 2021 Jan; 27(2):460-472. PubMed ID: 33148673
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Mettu NB; Ulahannan SV; Bendell JC; Garrido-Laguna I; Strickler JH; Moore KN; Stagg R; Kapoun AM; Faoro L; Sharma S
Clin Cancer Res; 2022 Mar; 28(5):882-892. PubMed ID: 34844977
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Sanborn RE; Pishvaian MJ; Callahan MK; Weise A; Sikic BI; Rahma O; Cho DC; Rizvi NA; Sznol M; Lutzky J; Bauman JE; Bitting RL; Starodub A; Jimeno A; Reardon DA; Kaley T; Iwamoto F; Baehring JM; Subramaniam DS; Aragon-Ching JB; Hawthorne TR; Rawls T; Yellin M; Keler T
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35940825
[TBL] [Abstract][Full Text] [Related]
16. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Tannir NM; Papadopoulos KP; Wong DJ; Aljumaily R; Hung A; Afable M; Kim JS; Ferry D; Drakaki A; Bendell J; Naing A
Int J Cancer; 2021 Jul; 149(2):403-408. PubMed ID: 33709428
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
Weiss SA; Djureinovic D; Jessel S; Krykbaeva I; Zhang L; Jilaveanu L; Ralabate A; Johnson B; Levit NS; Anderson G; Zelterman D; Wei W; Mahajan A; Trifan O; Bosenberg M; Kaech SM; Perry CJ; Damsky W; Gettinger S; Sznol M; Hurwitz M; Kluger HM
Clin Cancer Res; 2021 Sep; 27(17):4757-4767. PubMed ID: 34140403
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
Nadal E; Saleh M; Aix SP; Ochoa-de-Olza M; Patel SP; Antonia S; Zhao Y; Gueorguieva I; Man M; Estrem ST; Liu J; Avsar E; Lin WH; Benhadji KA; Gandhi L; Guba SC; Diaz IA
BMC Cancer; 2023 Jul; 23(1):708. PubMed ID: 37507657
[TBL] [Abstract][Full Text] [Related]
19. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
McDermott DF; Drake CG; Sznol M; Choueiri TK; Powderly JD; Smith DC; Brahmer JR; Carvajal RD; Hammers HJ; Puzanov I; Hodi FS; Kluger HM; Topalian SL; Pardoll DM; Wigginton JM; Kollia GD; Gupta A; McDonald D; Sankar V; Sosman JA; Atkins MB
J Clin Oncol; 2015 Jun; 33(18):2013-20. PubMed ID: 25800770
[TBL] [Abstract][Full Text] [Related]
20. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
